Anebulo Pharmaceuticals Inc (ANEB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Anebulo Pharmaceuticals Inc (ANEB) has a cash flow conversion efficiency ratio of -0.165x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.31 Million) by net assets ($7.94 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Anebulo Pharmaceuticals Inc worth for the company's overall valuation and market capitalisation.
Anebulo Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Anebulo Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Anebulo Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anebulo Pharmaceuticals Inc ranked by their cash flow conversion efficiency. See ANEB operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WAPS Co. Ltd
KQ:196700
|
0.038x |
|
Biotechnology Assets S.A.
MC:BST
|
0.102x |
|
Powerhouse Ventures Ltd
AU:PVL
|
-0.030x |
|
Malpac Holdings Bhd
KLSE:4936
|
0.000x |
|
Finlay Minerals Ltd
V:FYL
|
0.037x |
|
DeepMarkit Corp
V:MKT
|
-0.522x |
|
Unimit Engineering Public Company Limited
BK:UEC
|
0.018x |
|
Dadi Early-Childhood Education Group Ltd
TWO:8437
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Anebulo Pharmaceuticals Inc (2020–2025)
The table below shows the annual cash flow conversion efficiency of Anebulo Pharmaceuticals Inc from 2020 to 2025. View Anebulo Pharmaceuticals Inc (ANEB) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $11.66 Million | $-6.35 Million | -0.545x | +74.33% |
| 2024-06-30 | $3.81 Million | $-8.09 Million | -2.122x | -132.34% |
| 2023-06-30 | $10.60 Million | $-9.68 Million | -0.913x | -153.11% |
| 2022-06-30 | $15.07 Million | $-5.44 Million | -0.361x | -58.62% |
| 2021-06-30 | $21.41 Million | $-4.87 Million | -0.227x | -323.19% |
| 2020-06-30 | $2.80 Million | $-150.77K | -0.054x | -- |
About Anebulo Pharmaceuticals Inc
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical tria… Read more